| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acquired Immunodeficiency Syndrome–Related Lymphoma in the Era of Highly Active Antiretroviral Therapy
|
Thirlwell, Christina
|
|
2003
|
|
2 |
p. 86-92
7 p.
|
artikel
|
| 2 |
A Prospective, Open-Label Safety and Efficacy Study of Combination Treatment with Bortezomib (PS-341, Velcade™) and Melphalan in Patients with Relapsed or Refractory Multiple Myeloma
|
Yang, Hank H.
|
|
2003
|
|
2 |
p. 119-122
4 p.
|
artikel
|
| 3 |
A Prospective, Open-Label Safety and Efficacy Study of Combination Treatment with Melphalan, Arsenic Trioxide, and Ascorbic Acid in Patients with Relapsed or Refractory Multiple Myeloma
|
Berenson, James R.
|
|
2004
|
|
2 |
p. 130-134
5 p.
|
artikel
|
| 4 |
A Randomized, Placebo-Controlled Study of Outpatient Premedication for Bone Marrow Biopsy in Adults with Lymphoma
|
Wolanskyj, Alexandra P.
|
|
2000
|
|
2 |
p. 154-157
4 p.
|
artikel
|
| 5 |
Are Radiometal-Labeled Antibodies Better Than Iodine-131–Labeled Antibodies: Comparative Pharmacokinetics and Dosimetry of Copper-67–, Iodine-131–, and Yttrium-90–Labeled Lym-1 Antibody in Patients with Non-Hodgkin's Lymphoma
|
DeNardo, Gerald L.
|
|
2000
|
|
2 |
p. 118-126
9 p.
|
artikel
|
| 6 |
Campath-1H for Chronic Lymphocytic Leukemia
|
Rai, Kanti R.
|
|
2002
|
|
2 |
p. 73-74
2 p.
|
artikel
|
| 7 |
Can [18F]Fluorodeoxyglucose Positron Emission Tomography Replace Bone Marrow Biopsy in Staging of Malignant Lymphoma?
|
Naumann, Ralph
|
|
2004
|
|
2 |
p. 127-
1 p.
|
artikel
|
| 8 |
Commentary on “Cutaneous Manifestations of Lymphoma: A Clinical Guide Based on the WHO Classification”
|
Willemze, Rein
|
|
2001
|
|
2 |
p. 101-102
2 p.
|
artikel
|
| 9 |
Commentary on “DAB389IL-2 (ONTAK): A Novel Fusion Toxin Therapy for Lymphoma”
|
LeMaistre, Charles F.
|
|
2000
|
|
2 |
p. 117-
1 p.
|
artikel
|
| 10 |
Commentary on “Excellent Tolerance of Rituximab When Given After Mitoxantrone/Cyclophosphamide: An Effective and Safe Combination for Indolent Non-Hodgkin's Lymphoma”
|
McLaughlin, Peter
|
|
2000
|
|
2 |
p. 152-153
2 p.
|
artikel
|
| 11 |
Commentary on “High-Dose Methotrexate for Isolated Central Nervous System Relapse in Patients with Testicular Non-Hodgkin's Lymphoma”
|
DeAngelis, Lisa M.
|
|
2001
|
|
2 |
p. 120-
1 p.
|
artikel
|
| 12 |
Commentary on “High-Dose Methotrexate for Isolated Central Nervous System Relapse in Patients with Testicular Non-Hodgkin's Lymphoma”
|
Solomon, Benjamin
|
|
2001
|
|
2 |
p. 121-122
2 p.
|
artikel
|
| 13 |
Commentary on “The History of the Development of Vaccines for the Treatment of Lymphoma”
|
Warren, Thomas L.
|
|
2000
|
|
2 |
p. 140-
1 p.
|
artikel
|
| 14 |
Cutaneous Manifestations of Lymphoma: A Clinical Guide Based on the WHO Classification
|
Sander, Christian A.
|
|
2001
|
|
2 |
p. 86-100
15 p.
|
artikel
|
| 15 |
Cytomegalovirus Viremia During Campath-1H Therapy for Relapsed and Refractory Chronic Lymphocytic Leukemia and Prolymphocytic Leukemia
|
Nguyen, Dorothy D.
|
|
2002
|
|
2 |
p. 105-110
6 p.
|
artikel
|
| 16 |
DAB389IL-2 (ONTAK): A Novel Fusion Toxin Therapy for Lymphoma
|
Foss, Francine M.
|
|
2000
|
|
2 |
p. 110-116
7 p.
|
artikel
|
| 17 |
Does Positron Emission Tomography Have a Role in Routine Clinical Practice in Patients with Hodgkin's Disease?
|
Jerusalem, Guy H.M.
|
|
2002
|
|
2 |
p. 125-126
2 p.
|
artikel
|
| 18 |
Dose-Intense Cyclophosphamide and Etoposide for Patients with Refractory or High-Risk Non-Hodgkin's Lymphoma
|
Talbot, Jeffrey
|
|
2004
|
|
2 |
p. 116-122
7 p.
|
artikel
|
| 19 |
Editorial
|
Jain, Vinay K.
|
|
2001
|
|
2 |
p. 73-
1 p.
|
artikel
|
| 20 |
Enterococcal Eschars in Cutaneous T-Cell Lymphoma Tumors: A Distinct Clinical Entity
|
Duvic, Madeleine
|
|
2000
|
|
2 |
p. 141-145
5 p.
|
artikel
|
| 21 |
Excellent Tolerance of Rituximab When Given After Mitoxantrone/Cyclophosphamide: An Effective and Safe Combination for Indolent Non-Hodgkin's Lymphoma
|
Emmanouilides, Christos
|
|
2000
|
|
2 |
p. 146-151
6 p.
|
artikel
|
| 22 |
Fourteen-Day CHOP Supported with Granulocyte Colony-Stimulating Factor in Patients with Aggressive Non-Hodgkin's Lymphoma: Results of a Phase II Study
|
Gregory, Stephanie A.
|
|
2003
|
|
2 |
p. 93-98
6 p.
|
artikel
|
| 23 |
Gemcitabine and Its Combinations in the Treatment of Malignant Lymphoma
|
Chau, Ian
|
|
2002
|
|
2 |
p. 97-104
8 p.
|
artikel
|
| 24 |
Hepatic Failure as the Presenting Manifestation of Malignant Lymphoma
|
Thompson, Donald R.
|
|
2001
|
|
2 |
p. 123-128
6 p.
|
artikel
|
| 25 |
High-Dose Methotrexate for Isolated Central Nervous System Relapse in Patients with Testicular Non-Hodgkin's Lymphoma
|
Batchelor, Tracy
|
|
2001
|
|
2 |
p. 116-119
4 p.
|
artikel
|
| 26 |
Highlights from: 36th Annual American Society of Clinical Oncology Meeting, New Orleans, LA, May 20-23, 2000
|
Fisher, Maxine D.
|
|
2000
|
|
2 |
p. 93-100
8 p.
|
artikel
|
| 27 |
Highlights From: 40th Annual Meeting of the American Society of Clinical Oncology; June 2004 New Orleans, Louisiana
|
Price, Nancy
|
|
2004
|
|
2 |
p. 74-80
7 p.
|
artikel
|
| 28 |
Highlights From: 39th Annual Meeting of the American Society of Clinical Oncology;May 31 to June 3, 2003 Chicago, Illinois
|
Klem, Jennifer
|
|
2003
|
|
2 |
p. 73-78
6 p.
|
artikel
|
| 29 |
Highlights From: 6th European Hematology Association Meeting, Frankfurt, Germany June 21–24, 2001
|
Maung, Kavita
|
|
2001
|
|
2 |
p. 74-79
6 p.
|
artikel
|
| 30 |
Highlights From: VIII International Conference on Malignant Lymphoma June 12–15, 2002 Lugano, Switzerland
|
Gibson, Angelia D.
|
|
2002
|
|
2 |
p. 75-81
7 p.
|
artikel
|
| 31 |
Impact of Dose-Intense and Dose-Dense Approaches on Outcome in Aggressive Non-Hodgkin's Lymphoma
|
Gibson, Angelia D.
|
|
2003
|
|
2 |
p. 83-85
3 p.
|
artikel
|
| 32 |
Iodine-131 Tositumomab (Bexxar™) Has Activity in Transformed Low-Grade Non-Hodgkin's Lymphoma
|
|
|
2000
|
|
2 |
p. 104-105
2 p.
|
artikel
|
| 33 |
Lymphomas and Oncolytic Virus Therapy
|
Alain, Tommy
|
|
2003
|
|
2 |
p. 104-111
8 p.
|
artikel
|
| 34 |
Mantle Cell Lymphoma: New Treatments Targeted to the Biology
|
Bertoni, Francesco
|
|
2002
|
|
2 |
p. 90-96
7 p.
|
artikel
|
| 35 |
Mitoxantrone/Ifosfamide/Etoposide Salvage Regimen with Rituximab for In Vivo Purging in Patients with Relapsed Lymphoma
|
Emmanouilides, Christos
|
|
2002
|
|
2 |
p. 111-116
6 p.
|
artikel
|
| 36 |
Molecular Diagnostics in Low-Grade Gastric Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue Type After Helicobacter pylori Eradication Therapy
|
Alpen, Birgit
|
|
2001
|
|
2 |
p. 103-108
6 p.
|
artikel
|
| 37 |
Multimodality Treatment in a Case of Primary Cardiac Lymphoma
|
Lo, Shelly S.
|
|
2003
|
|
2 |
p. 112-114
3 p.
|
artikel
|
| 38 |
Mutational Status of IgVH Genes Consistent with Antigen-Driven Selection but Not Percent of Mutations Has Prognostic Impact in B-Cell Chronic Lymphocytic Leukemia
|
Degan, Massimo
|
|
2004
|
|
2 |
p. 123-126
4 p.
|
artikel
|
| 39 |
Non-Hodgkin's Lymphoma in the Microarray Era
|
Lossos, Izidore S.
|
|
2004
|
|
2 |
p. 128-129
2 p.
|
artikel
|
| 40 |
Pathology of Primary Cutaneous B-Cell Lymphomas: Diagnosis and Classification
|
Hsi, Eric D.
|
|
2004
|
|
2 |
p. 89-97
9 p.
|
artikel
|
| 41 |
Phase II Trials of Bortezomib (PS-341, Velcade™), a Selective Proteasome Inhibitor, in Non-Hodgkin's Lymphoma
|
Gibson, Angelia D.
|
|
2003
|
|
2 |
p. 79-82
4 p.
|
artikel
|
| 42 |
Primary Gastrointestinal Non-Hodgkin's Lymphoma: Treatment Outcome
|
Al-Shemmari, Salem H.
|
|
2003
|
|
2 |
p. 99-103
5 p.
|
artikel
|
| 43 |
Primary Large-Cell Non-Hodgkin's Lymphoma of the Testis: A Retrospective Analysis of Patterns of Failure and Prognostic Factors
|
Seymour, John F.
|
|
2001
|
|
2 |
p. 109-115
7 p.
|
artikel
|
| 44 |
Progress in the Prognosis of Adult Hodgkin's Lymphoma in the Past 35 Years Through Clinical Trials in Argentina: A GATLA Experience
|
Pavlovsky, Santiago
|
|
2004
|
|
2 |
p. 102-109
8 p.
|
artikel
|
| 45 |
Randomized Study of IDEC-Y2B8 (Zevalin™) Compared to Rituximab for B-Cell NHL
|
|
|
2000
|
|
2 |
p. 106-107
2 p.
|
artikel
|
| 46 |
Recombinant Immunotoxins in the Treatment of Hodgkin's Lymphoma
|
Fisher, Maxine D.
|
|
2001
|
|
2 |
p. 84-85
2 p.
|
artikel
|
| 47 |
Results of a Phase II Multicenter Trial of Single-Agent Gemcitabine in Patients with Relapsed or Chemotherapy-Refractory Hodgkin's Lymphoma
|
Venkatesh, Hemachandra
|
|
2004
|
|
2 |
p. 110-115
6 p.
|
artikel
|
| 48 |
Rituximab Improves Rate and Duration of Chemotherapy-Induced Remissions in Indolent and Aggressive Non-Hodgkin's Lymphoma
|
Gibson, Angelia D.
|
|
2004
|
|
2 |
p. 81-83
3 p.
|
artikel
|
| 49 |
Rituximab in Lymphocyte Predominance Hodgkin's Disease: A Case Series
|
Ibom, Valerie K.
|
|
2003
|
|
2 |
p. 115-118
4 p.
|
artikel
|
| 50 |
Simultaneous Occurrence of Hodgkin's Lymphoma and Eosinophilic Granuloma: A Potential Pitfall in Positron Emission Tomography Imaging
|
Naumann, Ralph
|
|
2002
|
|
2 |
p. 121-124
4 p.
|
artikel
|
| 51 |
Spontaneous (Pathological) Splenic Rupture in a Blastic Variant of Mantle Cell Lymphoma: A Case Report and Literature Review
|
Lunning, Matthew A.
|
|
2002
|
|
2 |
p. 117-120
4 p.
|
artikel
|
| 52 |
The Expanding Frontier of Radioimmunotherapy of Relapsed Non-Hodgkin's Lymphoma
|
Kozuch, Peter
|
|
2000
|
|
2 |
p. 158-159
2 p.
|
artikel
|
| 53 |
The History of the Development of Vaccines for the Treatment of Lymphoma
|
Timmerman, John M.
|
|
2000
|
|
2 |
p. 129-139
11 p.
|
artikel
|
| 54 |
The Impact of Conventional and High-Dose Therapy for Lymphoma on Fertility
|
Grigg, Andrew
|
|
2004
|
|
2 |
p. 84-88
5 p.
|
artikel
|
| 55 |
Updated Metaanalysis Finds That Interferon-α Improves Progression-Free and Overall Survival in Low-Grade Non-Hodgkin's Lymphoma When Administered with Chemotherapy That Contains Anthracyclines or Mitoxantrone
|
Gibson, Angelia D.
|
|
2002
|
|
2 |
p. 82-84
3 p.
|
artikel
|
| 56 |
Updated Results of a Phase III Trial Comparing Ibritumomab Tiuxetan with Rituximab in Previously Treated Patients with Non-Hodgkin's Lymphoma
|
Gibson, Angelia D.
|
|
2002
|
|
2 |
p. 87-89
3 p.
|
artikel
|
| 57 |
Update of the French Studies of Autologous Transplantation in Multiple Myeloma
|
Fisher, Maxine D.
|
|
2001
|
|
2 |
p. 80-83
4 p.
|
artikel
|
| 58 |
Yttrium 90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rates and Durable Remissions in Patients with Previously Treated B-Cell Lymphoma
|
Gordon, Leo I.
|
|
2004
|
|
2 |
p. 98-101
4 p.
|
artikel
|
Tijdschrift beschrijving